Q&A

CRISPR In The Clinic: Regulatory Experts Discuss Development Of Cell And Gene Therapies

By Rebecca Roberts, PH.D. and Lina Jamis, M.S.

GettyImages-1445640967 RNA therapy

Moving through the regulatory space is often challenging for scientists trying to push their CRISPR therapies from the lab through clinical trials. Synthego not only provides GMP-grade sgRNAs; they also offer unparalleled regulatory expertise, partnering with CRISPR therapy sponsors to help them along their clinical development journey.

Synthego’s regulatory expert, Lina Jamis, provides answers to several questions including what regulatory experts do, why the clinical development of CRISPR therapy products is so time-consuming, issues with preparing regulatory documentation, and the ways Synthego can accelerate your path from bench to clinic. You will also learn more about regulatory documentation for Cell and Gene Therapy sponsors and regulatory trends and the future of CRISPR therapies.

access the Q&A!

Get unlimited access to:

Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Cell & Gene? Subscribe today.

Subscribe to Cell & Gene X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Cell & Gene